Results 61 to 70 of about 27,986 (275)

Transthoracic echocardiography of hypertrophic cardiomyopathy in adults: a practical guideline from the British Society of Echocardiography

Echo Research and Practice, 2021
Hypertrophic cardiomyopathy (HCM) is common, inherited and characterised by unexplained thickening of the myocardium. The British Society of Echocardiography (BSE) has recently published a minimum dataset for transthoracic echocardiography detailing the ...
Lauren Turvey, Daniel X Augustine, Shaun Robinson, David Oxborough, Martin Stout, Nicola Smith, Allan Harkness, Lynne Williams, Richard P Steeds, William Bradlow   +9 more
doaj   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy [PDF]

, 2008
Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients.
Hina, Kazuyoshi, Kawamura, Hiroshi, Kusachi, Shozo, Matsuura, Hiroko, Murakami, Takashi, Ninomiya, Yoshifumi, Shinohata, Ryoko, Sogo, Taiji, Usui, Shinichi, Yamamoto, Keizo   +9 more
core   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Midventricular Obstructive Hypertrophic Cardiomyopathy during Pregnancy Complicated by Pulmonary Embolism: A Case Report

Case Reports in Medicine, 2012
Hypertrophic cardiomyopathy (HCM) with midventricular obstruction (MVO) is a rare condition occurring in 1% of HCM patients. It is characterized by asymmetric left ventricular hypertrophy with MVO and elevated intraventricular pressure gradients ...
Leila Abid, Ahmed Tounsi, Dorra Abid, Mourad Hentati, Samir Kammoun   +4 more
doaj   +1 more source

Left ventricular non-compaction: clinical features and cardiovascular magnetic resonance imaging [PDF]

, 2009
Background: It is apparent that despite lack of family history, patients with the morphological characteristics of left ventricular non-compaction develop arrhythmias, thrombo-embolism and left ventricular dysfunction.
A Keren, A Varghese, C Lofiego, D Chin, E Zambrano, EN Oechslin, F Ichida, Francisco Leyva, G Junga, G Tamborini, Harald Sandman, J Dusek, JA McCrohon, Kayvan Khadjooi, KC Patel, LW Eurlings, M Ritter, Noor UH Mohammed, Paul WX Foley, R Jenni, R Jenni, R Soler, RF Duncan, RG Assomull, RM Lang, RM Lauer, RT Murphy, S Pujadas, SE Petersen, Shajil Chalil, VMC Salemi, Y Daimon, Zaheer R Yousef   +32 more
core   +5 more sources

Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Longer‐term morbidity post septal myectomy (SM) in obstructive hypertrophic cardiomyopathy has not been well characterized at a national level.
Ahmed Altibi, Miriam Elman, Hailey Volk, Mohammad Alqabani, Michael Butzner, Howard Song, Ahmad Masri   +6 more
doaj   +1 more source

Assessment of myocardial function in obstructive hypertrophic cardiomyopathy cats with and without response to medical treatment by carvedilol

BMC Veterinary Research, 2019
Background Inconsistency of treatment response in cats with obstructive hypertrophic cardiomyopathy is well recognized. We hypothesized that the difference in response to beta-blockers may be caused by myocardial functional abnormalities.
Ryohei Suzuki, Yohei Mochizuki, Yunosuke Yuchi, Yuyo Yasumura, Takahiro Saito, Takahiro Teshima, Hirotaka Matsumoto, Hidekazu Koyama   +7 more
doaj   +1 more source

Pacing in hypertrophic obstructive cardiomyopathy: A randomized crossover study [PDF]

, 2017
Background Uncontrolled studies have shown that short atrioventricular delay dual chamber pacing reduces outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Although the exact mechanism of this beneficial effect is unclear, this seems a
Chojnowska, L., Daubert, C., Gras, D., Guize, L., Jeanrenaud, X., Kappenberger, L., Linde, C., McKenna, W., Meisel, E., Rydén, L., Sadoul, N.   +10 more
core  

Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: Long‐Term Follow‐Up of Deformations and Hemodynamics

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background A detailed evaluation of hemodynamics, supportive morphology, and deformation may help uncover the pathophysiology of hypertrophic obstructive cardiomyopathy (HOCM) and the changes wrought by alcohol septal ablation (ASA). Purpose To investigate the global cardiac volume, myocardial deformation, and hemodynamic characteristics ...
Kenichiro Suwa, Kazuto Ohno, Terumori Satoh, Ryota Sato, Keisuke Iguchi, Yuichiro Maekawa   +5 more
wiley   +1 more source